StockData
Allarity Therapeutics, Inc. logo

Allarity Therapeutics, Inc. (ALLR) stock

ALLRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.79−0.08 (-9.25%)

Close on Nov 20, 2026Market cap $12.49MP/E –Yield –

Allarity Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

For fiscal 2025 it was -$14.83M. The highest annual figure on record is -$7.25M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$14.83M–
FY2024Dec 31, 2024-$17.65M–
FY2023Dec 31, 2023-$12.75M–
FY2022Dec 31, 2022-$16.84M–
FY2020Dec 31, 2020-$7.25M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.56M–
Q1 FY2026Mar 31, 2026-$4.56M–
Q2 FY2025Jun 30, 2025-$5.48M–
Q1 FY2025Mar 31, 2025-$2.69M–

More Allarity Therapeutics figures

See a number that looks wrong?